## Clinical Diagnosis: Statin-Induced Myositis This patient has symptomatic statin-induced myopathy with myalgia and elevated CK (1200 U/L = 6× upper limit of normal). The temporal relationship (symptoms after atorvastatin initiation) and objective CK elevation confirm drug-induced muscle injury requiring immediate action. ## Why Option B Is Correct: Discontinue Atorvastatin, Switch to Rosuvastatin 5 mg After CK Normalizes **Key Point:** When a patient develops statin-induced myositis with CK elevation >5× ULN, the statin must be **immediately discontinued**. After CK normalizes and symptoms resolve, rechallenge with a hydrophilic, low-CYP3A4-metabolized statin at a low dose is the standard approach. Both pravastatin and rosuvastatin are acceptable for rechallenge; however, **rosuvastatin 5 mg** is increasingly preferred in post-MI patients because it provides superior LDL-C reduction at low doses compared to pravastatin 40 mg, which is critical for secondary prevention targets (LDL-C < 70 mg/dL). **High-Yield:** Atorvastatin is lipophilic and metabolized extensively by CYP3A4, predisposing it to muscle accumulation and myotoxicity. Rosuvastatin is hydrophilic, minimally metabolized by CYP2C9 (not CYP3A4), and has a lower muscle penetration profile — making it a preferred rechallenge agent per ACC/AHA guidelines. **Clinical Pearl:** In secondary prevention post-MI, high-intensity statin therapy is mandated (ACC/AHA 2018 guidelines). Pravastatin 40 mg is a **moderate-intensity** statin and does not meet the high-intensity threshold required for this patient. Rosuvastatin 5–10 mg, while low-dose, can be titrated upward and represents a safer rechallenge strategy that can eventually achieve high-intensity goals. ## Statin Metabolism and Muscle Toxicity Risk | Statin | CYP Metabolism | Lipophilicity | Muscle Risk | Post-MI Intensity | |--------|----------------|---------------|-------------|-------------------| | Atorvastatin | CYP3A4 (High) | Lipophilic | High | High-intensity | | Simvastatin | CYP3A4 (High) | Lipophilic | High | Moderate | | Lovastatin | CYP3A4 (High) | Lipophilic | High | Moderate | | **Pravastatin** | **Minimal** | **Hydrophilic** | **Low** | **Moderate only** | | **Rosuvastatin** | **CYP2C9 (Minimal)** | **Hydrophilic** | **Low** | **High-intensity (≥20 mg)** | ## Management Algorithm for Statin-Induced Myopathy ``` CK elevated + symptomatic ↓ Discontinue statin IMMEDIATELY ↓ Monitor CK every 2–4 weeks until normalized ↓ Rechallenge with hydrophilic statin at LOW dose (Rosuvastatin 5 mg preferred in post-MI for titration potential) ↓ Titrate dose; recheck CK and lipids at 4–6 weeks ↓ If recurrence → non-statin therapy (ezetimibe ± PCSK9 inhibitor) ``` ## Why Other Options Are Incorrect **Option A – Switch to pravastatin 40 mg daily:** Pravastatin is hydrophilic and low-risk for myopathy, making it a valid rechallenge agent. However, it is a **moderate-intensity** statin and does not meet ACC/AHA secondary prevention targets for post-MI patients (who require high-intensity therapy). Additionally, switching without first discontinuing and allowing CK normalization is inappropriate when CK is 6× ULN. This option also omits the critical step of waiting for CK normalization before rechallenge. **Option C – Continue atorvastatin and add CoQ10:** Continuing a statin when CK is 6× ULN and the patient is symptomatic risks progression to **rhabdomyolysis**, acute kidney injury, and death. CoQ10 supplementation has NOT been proven to prevent or treat statin myopathy in randomized controlled trials (Cochrane review, 2015). This option is dangerous and incorrect. **Option D – Discontinue atorvastatin and initiate ezetimibe 10 mg daily:** Ezetimibe monotherapy is insufficient for secondary prevention post-MI. While ezetimibe reduces LDL-C by ~18–20%, it lacks the mortality benefit demonstrated by statins in post-MI patients (IMPROVE-IT trial showed benefit only as an *add-on* to statin therapy). Abandoning statin therapy entirely without attempting rechallenge is not guideline-concordant unless true statin intolerance is confirmed after multiple rechallenge attempts. ## Clinical Management Summary 1. **Immediate:** Discontinue atorvastatin 2. **Monitoring:** Repeat CK every 2–4 weeks; expect normalization within 4–6 weeks 3. **Rechallenge:** Start rosuvastatin 5 mg daily once CK normalizes and symptoms resolve 4. **Titration:** Increase rosuvastatin dose gradually toward high-intensity (20–40 mg) as tolerated 5. **Adjunct:** Consider adding ezetimibe if LDL-C targets not met on low-dose rosuvastatin 6. **Counseling:** Report any recurrence of muscle symptoms immediately **Reference:** ACC/AHA 2018 Cholesterol Guidelines; KD Tripathi Essentials of Medical Pharmacology, 8th ed.; Harrison's Principles of Internal Medicine, 21st ed.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.